Bicyclic and bridged nitrogen heterocycles

Details Bicyclic and bridged nitrogen heterocycles Bicyclic and bridged nitrogen heterocycles

2005-09-01

2008-10-14

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07435831

ABSTRACT:
Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.

REFERENCES:
patent: 3362956 (1968-01-01), Archer
patent: 3478032 (1969-11-01), Arya
patent: 3491098 (1970-01-01), Archer
patent: 3723433 (1973-03-01), Ueno et al.
patent: 3950354 (1976-04-01), Wenzelburger et al.
patent: 3994890 (1976-11-01), Fujimura et al.
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4174393 (1979-11-01), Van Daalen et al.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4310429 (1982-01-01), Lai
patent: 4442102 (1984-04-01), Heinemann et al.
patent: 4547505 (1985-10-01), Oepen et al.
patent: 4559341 (1985-12-01), Petersen et al.
patent: 4562189 (1985-12-01), Tomcufcik et al.
patent: 4672063 (1987-06-01), Jasserand et al.
patent: 4772604 (1988-09-01), van Wijngaarden et al.
patent: 4880809 (1989-11-01), Sugihara et al.
patent: 4997836 (1991-03-01), Sugihara et al.
patent: 5011928 (1991-04-01), Venero et al.
patent: 5177078 (1993-01-01), Ward et al.
patent: 5215989 (1993-06-01), Baldwin et al.
patent: 5227486 (1993-07-01), Merce-Vidal et al.
patent: 5292739 (1994-03-01), Merce-Vidal et al.
patent: 5346896 (1994-09-01), Ward et al.
patent: 5382586 (1995-01-01), Merce-Vidal et al.
patent: 5464788 (1995-11-01), Bock et al.
patent: 5580985 (1996-12-01), Lee et al.
patent: 5607936 (1997-03-01), Chiang et al.
patent: 5646151 (1997-07-01), Kruse et al.
patent: 5681954 (1997-10-01), Yamamoto et al.
patent: 5719156 (1998-02-01), Shue et al.
patent: 5756504 (1998-05-01), Bock et al.
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5760225 (1998-06-01), Yuan
patent: 5780475 (1998-07-01), Baker et al.
patent: 5798359 (1998-08-01), Shue et al.
patent: 5968938 (1999-10-01), Williams et al.
patent: 6043246 (2000-03-01), Fukami et al.
patent: 6114334 (2000-09-01), Kerrigan et al.
patent: 6191159 (2001-02-01), Pinto
patent: 6207665 (2001-03-01), Bauman et al.
patent: 6288083 (2001-09-01), Luly et al.
patent: 6329385 (2001-12-01), Luly et al.
patent: 6384035 (2002-05-01), Hutchings et al.
patent: 6451399 (2002-09-01), Boyce
patent: 6455544 (2002-09-01), Friedhoff et al.
patent: 6469041 (2002-10-01), Yuan
patent: 6492375 (2002-12-01), Snutch
patent: 6518273 (2003-02-01), Chapman et al.
patent: 7157464 (2007-01-01), Pennell et al.
patent: 2002/0022624 (2002-02-01), Dinnell et al.
patent: 2002/0040020 (2002-04-01), Breitenbucher et al.
patent: 2002/0045613 (2002-04-01), Pauls et al.
patent: 2002/0045749 (2002-04-01), Li et al.
patent: 2002/0049205 (2002-04-01), Li et al.
patent: 2002/0077321 (2002-06-01), Khanna et al.
patent: 2002/0107255 (2002-08-01), Blumberg et al.
patent: 2002/0119961 (2002-08-01), Blumberg et al.
patent: 2003/0008893 (2003-01-01), Colon-Cruz et al.
patent: 2003/0087917 (2003-05-01), Strack et al.
patent: 2003/0139425 (2003-07-01), Bauman et al.
patent: 2003/0149021 (2003-08-01), Li et al.
patent: 2004/0162282 (2004-08-01), Pennell et al.
patent: 2005/0234034 (2005-10-01), Pennell et al.
patent: 2005/0256130 (2005-11-01), Pennell et al.
patent: 2006/0106218 (2006-05-01), Pennell et al.
patent: 0 479 546 (1992-04-01), None
patent: 1 006 110 (2000-06-01), None
patent: WO 97/10219 (1997-03-01), None
patent: WO 97/44329 (1997-11-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 98/39000 (1998-09-01), None
patent: WO 98/56771 (1998-12-01), None
patent: WO 99/07351 (1999-02-01), None
patent: WO 99/09984 (1999-03-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 99/32468 (1999-07-01), None
patent: WO 99/37619 (1999-07-01), None
patent: WO 99/37651 (1999-07-01), None
patent: WO 00/31032 (2000-06-01), None
patent: WO 00/46195 (2000-08-01), None
patent: WO 00/46196 (2000-08-01), None
patent: WO 00/46197 (2000-08-01), None
patent: WO 00/46198 (2000-08-01), None
patent: WO 00/46199 (2000-08-01), None
patent: WO 00/47539 (2000-08-01), None
patent: WO 00/53600 (2000-09-01), None
patent: WO 00/69815 (2000-11-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 00/69848 (2000-11-01), None
patent: WO 02/08221 (2002-01-01), None
patent: WO 02/14314 (2002-02-01), None
patent: WO 02/070523 (2002-09-01), None
patent: WO 03/008395 (2003-01-01), None
patent: WO 03/024450 (2003-03-01), None
patent: WO 03/051842 (2003-06-01), None
patent: WO 03/105853 (2003-12-01), None
patent: WO 2004/009550 (2004-01-01), None
patent: WO 2005/084667 (2005-09-01), None
Anders, et al., “A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.” J Clin Invest. (2002) 109(2):251-9.
Badran, M. et al., “Indazole derivatives (part III): synthesis of pyrazolo-[1,2-a]indazole-1,9-dione,[1,2,4]triazino[1,2-a]indazole-1,10-dione, 3-(Indazol-1-yl)propionic acid amides and hydrazides possessing potential biological activity”Alex. J. Pharm. Sci. (1999) 13(2):101-106.
Bebernitz, G. et al., “The effect of 1,3-diaryl-[1H]-pyrazole-4-acetamides on glucose utilization in on/ob mice”J. Med. Chem. (2001) 44:2601-2611.
Bendele, et al., “Animal models of arthritus: relevance to human disease,” Toxicologic Pathol. (1999) 27:134-142.
Berge, S.M., et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences (1977) 66:1-19.
Chemcats Database, Chemical Abstracting Service, Accession No. 2003:2855298, Jan. 1, 2004 for CAS Registry No. 492422-98-7.
Chemcats Database, Chemical Abstracting Service, Accession No. 2001:2759474, Oct. 20, 2003 for CAS Registry No. 351986-92-0.
Czarnocka-Janowicz, A. et al., “Synthesis and pharmacological activity of 5-substituted-s-triazole-3-thiols”Pharmazie(1991) 46:109-112.
Database Crossfire Beilstein ′Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession No. BRN 6982047 XP002254060 abstract & Varasi et al.,Farmaco Ed. Sci. (1987) 42(6):425-436.
Database Crossfire Beilstein ′Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession No. BRN 1159762 XP002254062 abstract & Zotta et al.Farmacia(1977) 25:129-134.
Database Crossfire Beilstein ′Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession No. BRN 6000843 XP002254061 abstract & Toja et al.,Heterocycles(1987) 26(8):2129-2138.
Database Crossfire Beilstein ′Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession No. BRN 9229443 XP002254063 abstract & Vovk, et al.,Russ. J. Org. Chem. (2001) 37(12).
Devries, M. et al., “On the edge: the physiological and pathophysiological role of chemokines during inflammatory and immunological responses”Sem. Immun. (1999) 11:95-104.
Fischer, F. et al., “Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression”J. Neuroimmun. (2000) 110:195-208.
Foks, H. et al., “Synthesis of new 5-substituted 1,2,4-triazole-3-thione derivatives”Phosphorus, Sulfur and Silicon(2000) 164:67-81.
Gao, et al., “Targeting of the chemokine receptor CCR-1 suppresses development of acute and chronic cardiac allograft rejection,” J Clin Invest. (2000) 105(1):35-44.
Hayao, S. et al., “New antihypertensive aminoalkyltetrazoles”J. Med. Chem. (1967) 10:400-402.
Hcaplus; Accession No. 1984:630511, Document No. 101:230511; Japanese Patent No. 59130890, issued Jul. 27, 1984; Abstract, 4 pages.
Hesselgesser, J. et al., “Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor”J. Biol. Chem. (1998) 273(25):1

Affiliated with

Also associated with

Rating

Bicyclic and bridged nitrogen heterocycles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic and bridged nitrogen heterocycles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic and bridged nitrogen heterocycles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3998390